# Alicia Iruzun Lafitte

> Alicia Iruzun Lafitte is a Series A investor at UCB Ventures backing Therapeutics. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [UCB Ventures](https://shizune.co/investors/profile/ucb-ventures)
- Location: Boston, United States
- Total investments: 4
- Last investment: Mar 2023
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/alicia-irurzun-lafitte-88508b15/

Alicia Iruzun Lafitte is a Series A investor at UCB Ventures in Boston focused on Therapeutics and Biotechnology. Alicia Irurzun-Lafitte joined UCB Ventures in March 2019 as Partner. Alicia joined from M Ventures, the corporate venture arm of Merck KGaA. Since 2014, she was instrumental in the closing of multiple new investments in Oncology, Immunology and Fertility areas in the US and Europe for the M Ventures Healthcare fund. Alicia was also closely involvedwith the built-up of Merck spin-offs. While at M Ventures, she served on the Board of Rewind Therapeutics as Director and Artios, iOnctura, Ribometrix, and TocopheRx as Observer.Prior to ventures, Alicia held roles in global business development at Merck Serono in Geneva and EMD Serono in Boston. During her time in business development she closed multiple early stage transactions and was involved in strategic corporate development initiatives.Alicia holds a MSc from Leiden University in Biopharmaceutical Sciences. She holds a Bachelor in Biomedical Sciences and completed her undergraduate studies between the University Claude Bernard Lyon 1 and Napier Edinburgh University.Alicia is based at the UCB Ventures' Boston office and she lives in New York.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 25% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Switch Therapeutics | Switch Therapeutics is a biotech company that develops RNAi therapies based on technology. The company was founded in 2020 and is based in San Francisco, California, United States. | $52M | Series A | Mar 14, 2023 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. |  | Series B | Jan 25, 2023 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. |  | Series A | Jan 25, 2023 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. | $16.7M | Series A | Jan 04, 2018 |  |

4 of 4 investments shown.

## Co-investors
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 3 deals together
- [Gemma Frisius Fund](https://shizune.co/investors/profile/gemma-frisius-fund) — VC Fund, 3 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 3 deals together
- [Centre for Drug Design & Discovery (CD3)](https://shizune.co/investors/profile/centre-for-drug-design-discovery-cd3) — VC Fund, 2 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 2 deals together
- [Bold Capital Partners](https://shizune.co/investors/profile/bold-capital) — VC Fund, 1 deal together

## About UCB Ventures

VC Fund · Brussels, Belgium

UCB Ventures is a €150 million strategic corporate venture fund

5 contacts available at UCB Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Alicia Iruzun Lafitte | Partner | https://shizune.co/investors/profile/alicia-iruzun-lafitte |
| Emmanuel Lacroix | Partner | https://shizune.co/investors/profile/emmanuel-lacroix |
| Delphine Hajaji | Partner | https://shizune.co/investors/profile/delphine-hajaji |
| Erica Whittaker | Head of UCB Ventures | https://shizune.co/investors/profile/erica-whittaker |
| Joshua Sands | Principal | https://shizune.co/investors/profile/joshua-sands |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Alicia Iruzun Lafitte invest in?

Alicia Iruzun Lafitte invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alicia Iruzun Lafitte last invest?

The most recent investment recorded for Alicia Iruzun Lafitte closed in Mar 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co